Equities research analysts at StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Get Free Report) in a research report issued to clients and investors on Friday. The firm set a “hold” rating on the stock.
TherapeuticsMD Price Performance
TXMD stock opened at $1.90 on Friday. TherapeuticsMD has a twelve month low of $1.86 and a twelve month high of $4.73. The business’s fifty day moving average is $2.27 and its 200-day moving average is $2.34.
Hedge Funds Weigh In On TherapeuticsMD
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC raised its stake in TherapeuticsMD by 339.2% during the 2nd quarter. Millennium Management LLC now owns 57,657 shares of the company’s stock worth $574,000 after buying an additional 44,528 shares during the period. BlackRock Inc. grew its stake in TherapeuticsMD by 18.1% in the second quarter. BlackRock Inc. now owns 137,127 shares of the company’s stock valued at $565,000 after acquiring an additional 20,995 shares during the period. Geode Capital Management LLC bought a new stake in shares of TherapeuticsMD in the fourth quarter worth about $374,000. Royal Bank of Canada raised its position in shares of TherapeuticsMD by 688.1% during the first quarter. Royal Bank of Canada now owns 788,446 shares of the company’s stock worth $299,000 after purchasing an additional 688,399 shares during the period. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of TherapeuticsMD during the fourth quarter worth about $249,000. 30.74% of the stock is owned by institutional investors.
About TherapeuticsMD
TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
Featured Articles
- Five stocks we like better than TherapeuticsMD
- What is the Australian Securities Exchange (ASX)
- Comprehensive PepsiCo Stock Analysis
- What Does Downgrade Mean in Investing?
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.
